Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ERYTECH Pharma

DB:2E4A
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2E4A
DB
€89M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
  • ERYTECH Pharma has significant price volatility in the past 3 months.
2E4A Share Price and Events
7 Day Returns
10.1%
DB:2E4A
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-
DB:2E4A
-13.2%
DE Biotechs
-20.9%
DE Market
2E4A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ERYTECH Pharma (2E4A) 10.1% -0.8% -13.1% - - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • No trading data on 2E4A.
  • No trading data on 2E4A.
Price Volatility
2E4A
Industry
5yr Volatility vs Market

2E4A Value

 Is ERYTECH Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ERYTECH Pharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ERYTECH Pharma.

DB:2E4A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2E4A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 33%) (15.94%))
1.211
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.21
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.211 * 6.07%)
6.96%

Discounted Cash Flow Calculation for DB:2E4A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ERYTECH Pharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:2E4A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 6.96%)
2020 -55.60 Analyst x2 -51.98
2021 11.00 Analyst x1 9.62
2022 14.50 Est @ 31.82% 11.85
2023 17.71 Est @ 22.16% 13.53
2024 20.44 Est @ 15.39% 14.60
2025 22.62 Est @ 10.66% 15.10
2026 24.28 Est @ 7.34% 15.16
2027 25.50 Est @ 5.02% 14.88
2028 26.36 Est @ 3.4% 14.39
2029 26.96 Est @ 2.26% 13.76
Present value of next 10 years cash flows €70.00
DB:2E4A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €26.96 × (1 + -0.39%) ÷ (6.96% – -0.39%)
€365.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €365.38 ÷ (1 + 6.96%)10
€186.43
DB:2E4A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €70.00 + €186.43
€256.43
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €256.43 / 17.94
€14.3
DB:2E4A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2E4A represents 0.96761x of ENXTPA:ERYP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96761x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 14.30 x 0.96761
€13.83
Value per share (EUR) From above. €13.83
Current discount Discount to share price of €4.78
= -1 x (€4.78 - €13.83) / €13.83
65.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ERYTECH Pharma is available for.
Intrinsic value
>50%
Share price is €4.78 vs Future cash flow value of €13.83
Current Discount Checks
For ERYTECH Pharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ERYTECH Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ERYTECH Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ERYTECH Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ERYTECH Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2E4A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-3.49
ENXTPA:ERYP Share Price ** ENXTPA (2020-04-03) in EUR €4.94
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ERYTECH Pharma.

DB:2E4A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ERYP Share Price ÷ EPS (both in EUR)

= 4.94 ÷ -3.49

-1.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ERYTECH Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ERYTECH Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ERYTECH Pharma's expected growth come at a high price?
Raw Data
DB:2E4A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
34.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ERYTECH Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ERYTECH Pharma's assets?
Raw Data
DB:2E4A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €4.77
ENXTPA:ERYP Share Price * ENXTPA (2020-04-03) in EUR €4.94
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:2E4A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ERYP Share Price ÷ Book Value per Share (both in EUR)

= 4.94 ÷ 4.77

1.04x

* Primary Listing of ERYTECH Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ERYTECH Pharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ERYTECH Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ERYTECH Pharma has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

2E4A Future Performance

 How is ERYTECH Pharma expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
34.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ERYTECH Pharma expected to grow at an attractive rate?
  • ERYTECH Pharma's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • ERYTECH Pharma's earnings growth is expected to exceed the Germany market average.
  • ERYTECH Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2E4A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2E4A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 34.1%
DB:2E4A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 63.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2E4A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2E4A Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 257 47 22 3
2023-12-31 125 6 -15 3
2022-12-31 47 -48 -56 3
2021-12-31 7 -29 -51 3
2020-12-31 6 -54 -64 3
2020-04-06
DB:2E4A Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 5 -43 -63
2019-09-30 6 -38 -52
2019-06-30 5 -43 -49
2019-03-31 4 -38
2018-12-31 4 -48 -38
2018-09-30 3 -42
2018-06-30 4 -31 -38
2018-03-31 3 -39
2017-12-31 3 -25 -34
2017-09-30 4 -27
2017-06-30 4 -23 -26
2017-03-31 5 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ERYTECH Pharma's earnings are expected to grow significantly at over 20% yearly.
  • ERYTECH Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2E4A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from ERYTECH Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2E4A Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.70 1.70 1.70 1.00
2023-12-31 -0.40 -0.40 -0.40 1.00
2022-12-31 -3.00 -3.00 -3.00 1.00
2021-12-31 -2.10 -1.09 -3.10 2.00
2020-12-31 -3.20 -3.20 -3.20 1.00
2020-04-06
DB:2E4A Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -3.49
2019-09-30 -2.89
2019-06-30 -2.71
2019-03-31
2018-12-31 -2.13
2018-09-30 -2.36
2018-06-30 -2.50
2018-03-31
2017-12-31 -2.95
2017-09-30
2017-06-30 -2.86
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ERYTECH Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess ERYTECH Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ERYTECH Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

2E4A Past Performance

  How has ERYTECH Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ERYTECH Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ERYTECH Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ERYTECH Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ERYTECH Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ERYTECH Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ERYTECH Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2E4A Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 5.28 -62.66 17.16 52.19
2019-09-30 5.66 -51.83 17.78 44.72
2019-06-30 5.15 -48.54 17.70 39.43
2019-03-31 4.00 -38.14 16.71 34.91
2018-12-31 4.45 -38.22 14.60 33.47
2018-09-30 3.17 -42.36 13.26 33.35
2018-06-30 3.84 -38.42 12.29 30.13
2018-03-31 3.35 -38.75 9.62 27.35
2017-12-31 3.36 -33.53 8.79 25.46
2017-09-30 3.73 -26.60 7.40 23.30
2017-06-30 3.52 -25.65 6.48 23.00
2017-03-31 4.68 -24.11 7.24 21.93
2016-12-31 4.14 -21.91 6.81 19.72
2016-09-30 4.05 -20.37 7.83 17.03
2016-06-30 3.97 -18.83 8.85 14.35
2016-03-31 2.93 -16.07 7.66 11.80
2015-12-31 2.93 -15.01 7.74 10.78
2015-09-30 2.69 -13.61 6.61 10.35
2015-06-30 2.45 -12.21 5.48 9.93
2015-03-31 2.12 -10.53 4.92 8.27
2014-12-31 1.80 -8.86 4.36 6.61
2014-09-30 1.65 -8.07 4.24 5.67
2014-06-30 1.51 -7.27 4.13 4.73
2014-03-31 1.59 -7.71 3.86 4.85
2013-12-31 1.66 -8.14 3.59 4.96
2013-09-30 3.96 -5.10 3.47 4.24
2013-06-30 6.25 -2.05 3.36 3.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ERYTECH Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ERYTECH Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ERYTECH Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ERYTECH Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ERYTECH Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

2E4A Health

 How is ERYTECH Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ERYTECH Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ERYTECH Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ERYTECH Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ERYTECH Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 57.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ERYTECH Pharma Company Filings, last reported 3 months ago.

DB:2E4A Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 85.56 1.42 73.19
2019-09-30 104.15 1.60 81.93
2019-06-30 117.03 1.73 94.45
2019-03-31 145.60 2.02 134.37
2018-12-31 145.60 1.98 134.37
2018-09-30
2018-06-30 163.81 2.35 165.42
2018-03-31 181.42 2.84 185.53
2017-12-31 181.42 2.73 185.53
2017-09-30
2017-06-30 87.67 3.08 88.55
2017-03-31 35.64 2.87 37.65
2016-12-31 35.64 2.66 37.65
2016-09-30 35.64 2.66 37.65
2016-06-30 37.60 0.55 36.47
2016-03-31 47.13 0.71 45.63
2015-12-31 47.13 0.56 45.63
2015-09-30 47.13 0.56 45.63
2015-06-30 30.72 0.54 31.05
2015-03-31 30.72 0.54 31.05
2014-12-31 35.82 0.55 36.99
2014-09-30 35.82 0.55 36.99
2014-06-30 11.18 0.71 12.29
2014-03-31 11.18 0.71 12.29
2013-12-31 13.59 0.71 15.11
2013-09-30 13.59 0.71 15.11
2013-06-30
  • ERYTECH Pharma's level of debt (1.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.5% vs 1.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ERYTECH Pharma has sufficient cash runway for 1.2 years based on current free cash flow.
  • Unable to confirm if ERYTECH Pharma has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess ERYTECH Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ERYTECH Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

2E4A Dividends

 What is ERYTECH Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ERYTECH Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of ERYTECH Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ERYTECH Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ERYTECH Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2E4A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2E4A Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ERYTECH Pharma has not reported any payouts.
  • Unable to verify if ERYTECH Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ERYTECH Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ERYTECH Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ERYTECH Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess ERYTECH Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ERYTECH Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ERYTECH Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

2E4A Management

 What is the CEO of ERYTECH Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gil Beyen
COMPENSATION €790,711
AGE 57
TENURE AS CEO 6.9 years
CEO Bio

Mr. Gil Beyen, BVBA has been the Chief Executive Officer of Erytech Pharma Société Anonyme (formerly, ERYtech Pharma SA) since May 2013. For more than ten years, Mr. Beyen has been a Management Consultant at Arthur D. Little in Brussels and serves as its Partner, responsible for their health industries and biotechnology sector. Mr. Beyen Co-founded TiGenix N.V., and served as its Chief Business Officer since May 3, 2011 and also as its Managing Director and Chief Executive Officer until May 3, 2011. He served for three years as a Researcher and Project Engineer in environmental biotechnology. He served as the Chairman of Erytech Pharma Société Anonyme (formerly, ERYtech Pharma SA ) from August 2013 to June 21, 2019 and has been its Director since May 6, 2013. He has been an Independent Director of Novadip Biosciences SA since 2015. He serves as a Non-Executive Director of VIB BV. He served as a Non-Executive Director at TiGenix N.V. until March 2014. Mr. Beyen holds an MSc in Bio-Engineering from the University of Leuven and obtained an MBA from the University of Chicago (U.S.A.) in 1990.

CEO Compensation
  • Gil's compensation has increased whilst company is loss making.
  • Gil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ERYTECH Pharma management team in years:

4.6
Average Tenure
55
Average Age
  • The tenure for the ERYTECH Pharma management team is about average.
Management Team

Gil Beyen

TITLE
CEO & Director
COMPENSATION
€791K
AGE
57
TENURE
6.9 yrs

Eric Soyer

TITLE
CFO, COO & Deputy GM
COMPENSATION
€454K
AGE
53
TENURE
4.6 yrs

Jérôme Bailly

TITLE
VP, Director of Pharmaceutical Operations & Deputy GM
COMPENSATION
€288K
AGE
40

Alexander Scheer

TITLE
Chief Scientific Officer
AGE
57
TENURE
3.5 yrs

Naomi Eichenbaum

TITLE
Director Investor Relations

Iman El-Hariry

TITLE
Chief Medical Officer
AGE
59
TENURE
4.8 yrs

Jean-Sébastien Cleiftie

TITLE
Chief Business Officer
AGE
46
TENURE
3.5 yrs

Philip Lorenzi

TITLE
Consultant & Member of Scientific Board

Eric Raymond

TITLE
Consultant & Member of Scientific Board

Bridget Bax

TITLE
Consultant & Member of Scientific Board
Board of Directors Tenure

Average tenure and age of the ERYTECH Pharma board of directors in years:

8.3
Average Tenure
58.5
Average Age
  • The tenure for the ERYTECH Pharma board of directors is about average.
Board of Directors

Jean-Paul Kress

TITLE
Independent Chairman of the Board
COMPENSATION
€170K
AGE
54
TENURE
0.8 yrs

Gil Beyen

TITLE
CEO & Director
COMPENSATION
€791K
AGE
57
TENURE
6.9 yrs

Philippe Archinard

TITLE
Independent Director
COMPENSATION
€66K
AGE
60
TENURE
6.9 yrs

Philip Lorenzi

TITLE
Consultant & Member of Scientific Board
TENURE
10.3 yrs

Eric Raymond

TITLE
Consultant & Member of Scientific Board
TENURE
10.5 yrs

Bridget Bax

TITLE
Consultant & Member of Scientific Board
TENURE
8.3 yrs

Arthur Frankel

TITLE
Consultant & Member of Scientific Board
TENURE
8.3 yrs

Kurt Gunter

TITLE
Consultant & Member of Scientific Board
AGE
64
TENURE
8.3 yrs

Hilde Windels

TITLE
Independent Director
COMPENSATION
€50K
AGE
54
TENURE
5.6 yrs

Sven Andréasson

TITLE
Independent Director
COMPENSATION
€59K
AGE
67
TENURE
10.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess ERYTECH Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ERYTECH Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

2E4A News

Simply Wall St News

2E4A Company Info

Description

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company’s lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen’s University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France.

Details
Name: ERYTECH Pharma S.A.
2E4A
Exchange: DB
Founded: 2004
€88,611,422
17,937,535
Website: http://www.erytech.com
Address: ERYTECH Pharma S.A.
60 Avenue Rockefeller,
Lyon,
Rhône-Alpes, 69008,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ERYP Category O Shares Euronext Paris FR EUR 30. Apr 2013
DB 2E4 Category O Shares Deutsche Boerse AG DE EUR 30. Apr 2013
LSE 0QSS Category O Shares London Stock Exchange GB EUR 30. Apr 2013
BATS-CHIXE ERYPP Category O Shares BATS 'Chi-X Europe' GB EUR 30. Apr 2013
NasdaqGS ERYP SPON ADR EACH REPR 1 ORD Nasdaq Global Select US USD 27. Mar 2015
DB 2E4A SPON ADR EACH REPR 1 ORD Deutsche Boerse AG DE EUR 27. Mar 2015
Number of employees
Current staff
Staff numbers
217
ERYTECH Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 02:51
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/20
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.